Cancer Pain Market Size, Share, Trends, Growth Outlook

Cancer Pain Market is estimated to increase at a growth rate of 5.2% CAGR over the forecast period from 2024 to 2030.

The Cancer Pain Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug (Opioids (Morphine, Fentanyl, Others), Non-Opioids (Acetaminophen, Non-Steroidal Anti-Inflammatory Drugs, Nerve Blockers)), By Disease (Lung Cancer, Colorectal cancer, Breast cancer, Prostate cancer, Blood cancer, Others).

An Introduction to Cancer Pain Market in 2024

The Cancer Pain market in 2024 addresses the management of pain associated with cancer diagnosis, treatment, and disease progression, focusing on optimizing pain relief, improving quality of life, and minimizing opioid-related side effects. Pain management modalities include pharmacological interventions such as opioids, adjuvant analgesics, and nerve blocks, as well as non-pharmacological approaches such as palliative care, physical therapy, and psychosocial support. Market dynamics are driven by factors such as the increasing prevalence of cancer-related pain, evolving pain management guidelines, and advancements in pain assessment and treatment modalities. Collaboration between oncologists, pain specialists, palliative care teams, and pharmaceutical companies drives innovation and accessibility in cancer pain management, aiming to address the complex needs of cancer patients and enhance their overall well-being.

Cancer Pain Market Trend: Integration of Palliative Care into Cancer Pain Management

A prominent trend in the Cancer Pain market is the integration of palliative care into cancer pain management. Healthcare providers are increasingly recognizing the importance of a holistic approach to cancer pain, which includes not only pharmacological interventions but also psychosocial, spiritual, and supportive care. Palliative care specialists collaborate with oncologists and pain management teams to address the multifaceted needs of cancer patients, ensuring comprehensive pain relief while improving quality of life. This trend reflects a shift towards patient-centered care and the recognition of pain management as an essential component of cancer treatment.

Cancer Pain Market Driver: Growing Cancer Incidence and Prevalence Worldwide

The primary driver for the Cancer Pain market is the growing incidence and prevalence of cancer worldwide. As cancer rates continue to rise globally, particularly in aging populations and developing countries, the number of individuals experiencing cancer-related pain also increases. Cancer pain can result from tumor growth, invasive procedures, treatment-related side effects, and metastasis, significantly impacting patients' physical and emotional well-being. The escalating demand for effective pain management solutions underscores the importance of developing and implementing tailored approaches to alleviate cancer-related pain and improve patients' quality of life.

Cancer Pain Market Opportunity: Advancements in Pain Management Therapies and Technologies

An opportunity in the Cancer Pain market lies in advancements in pain management therapies and technologies. Despite existing treatment options such as opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and adjuvant medications, many cancer patients still experience inadequate pain relief or intolerable side effects. There is a need for novel therapies and technologies that offer improved efficacy, safety, and convenience in managing cancer-related pain. Opportunities exist for the development of targeted analgesic agents, innovative drug delivery systems, minimally invasive procedures, and non-pharmacological interventions such as neuromodulation and integrative therapies. By investing in research and innovation, stakeholders in the Cancer Pain market can address unmet needs and enhance the standard of care for cancer patients experiencing pain.

Cancer Pain Market Segmentation

By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Cancer Pain Market Companies

BioDelivery Science
Daiichi Sankyo
Eli-Lilly
Galena Biopharma
Grunenthal Group
GW Pharmaceuticals
Hospira
Johnson & Johnson
Meda Pharmaceuticals
Orexo
ProStrakan Group
Sanofi
Sorrento Therapeutics
Teva pharmaceuticals
WEX Pharmaceuticals

 

 

Reasons to Buy the Cancer Pain Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cancer Pain Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cancer Pain Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Cancer Pain Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cancer Pain Market Size Outlook, $ Million, 2021 to 2030
3.2 Cancer Pain Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cancer Pain Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cancer Pain Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cancer Pain Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cancer Pain Market Industry
4.2 Key Market Trends in Cancer Pain Market Industry
4.3 Potential Opportunities in Cancer Pain Market Industry
4.4 Key Challenges in Cancer Pain Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Cancer Pain Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cancer Pain Market Outlook By Segments
7.1 Cancer Pain Market Outlook by Segments
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

8 North America Cancer Pain Market Analysis And Outlook To 2030
8.1 Introduction to North America Cancer Pain Markets in 2024
8.2 North America Cancer Pain Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cancer Pain Market size Outlook by Segments, 2021-2030
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

9 Europe Cancer Pain Market Analysis And Outlook To 2030
9.1 Introduction to Europe Cancer Pain Markets in 2024
9.2 Europe Cancer Pain Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cancer Pain Market Size Outlook By Segments, 2021-2030
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

10 Asia Pacific Cancer Pain Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Cancer Pain Markets in 2024
10.2 Asia Pacific Cancer Pain Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cancer Pain Market size Outlook by Segments, 2021-2030
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

11 South America Cancer Pain Market Analysis And Outlook To 2030
11.1 Introduction to South America Cancer Pain Markets in 2024
11.2 South America Cancer Pain Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cancer Pain Market size Outlook by Segments, 2021-2030
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

12 Middle East And Africa Cancer Pain Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Cancer Pain Markets in 2024
12.2 Middle East and Africa Cancer Pain Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cancer Pain Market size Outlook by Segments, 2021-2030
By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
BioDelivery Science
Daiichi Sankyo
Eli-Lilly
Galena Biopharma
Grunenthal Group
GW Pharmaceuticals
Hospira
Johnson & Johnson
Meda Pharmaceuticals
Orexo
ProStrakan Group
Sanofi
Sorrento Therapeutics
Teva pharmaceuticals
WEX Pharmaceuticals

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Type
Opioids
Morphine
Fentanyl
Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers
By Disease
Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others